JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Stage-specific role of IGFBP-3/TMEM219 pathway in liver fibrosis progression using a bile duct ligation rat model

  • 0Department of Clinical Biochemistry and Isfahan Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, I.R. of Iran.
Molecular Biology Reports +

|

August 25, 2025

|

August 25, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

The IGFBP-3/TMEM219 pathway drives liver fibrosis by promoting hepatocyte apoptosis. Targeting this pathway offers a potential therapeutic strategy for liver fibrosis.

Area Of Science

  • Hepatology
  • Molecular Biology
  • Pathology

Background

  • Liver fibrosis is a significant global health issue, often leading to cirrhosis.
  • Hepatocyte apoptosis is a key driver of liver fibrosis, but its molecular underpinnings are not fully understood.

Purpose Of The Study

  • To investigate the role of the Insulin-like Growth Factor Binding Protein 3 (IGFBP-3)/Transmembrane protein 219 (TMEM219) pathway in apoptosis-mediated liver fibrosis progression.

Main Methods

  • Liver fibrosis was induced in rats using bile duct ligation (BDL).
  • Serum biomarkers, histopathology, gene expression (IGFBP-3, TMEM219, HMOX1), and apoptotic markers (caspase 3/7, caspase 8) were analyzed.

Main Results

  • Bile duct ligation led to increased liver damage, collagen deposition, and elevated liver enzymes.
  • Gene expression analysis revealed significant upregulation of IGFBP-3 and TMEM219, with decreased HMOX1.
  • Apoptotic markers (caspase 3/7, caspase 8) significantly increased, correlating with fibrosis progression.

Conclusions

  • The IGFBP-3/TMEM219 pathway is crucial in mediating hepatocyte apoptosis and liver fibrosis progression in the BDL rat model.
  • This pathway represents a potential therapeutic target for managing liver fibrosis and its complications.

Keywords: